Parkinson\u27s Disease, Amantadine Hydrochloride Therapy and Dopa Metabolites

In an attempt to clarify the effect of amantadine hydrochloride therapy in Parkinson\u27s disease, dopa metabolites were measured in the urine of 15 patients who were taking this medication. The results indicated that patients on amantadine therapy had lower urinary levels of epinephrine plus norepinephrine than either normal individuals or parkinsonian patients not receiving amantadine. Patients who developed livedo reticularis during amantadine therapy showed a small but significant increase in urinary dopamine levels and a similar decrease in dopac levels, when compared to other patients on amantadine who did not develop livedo reticularis